Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Announcement regarding completion of the observation period for subjects in the global phase III clinical study of K-321
Announcement of completion of final observation in phase2 clinical trial of DWR-2206 and commencement of preparations for phase3 clinical trial
Consolidated Financial Results for the Nine Months Ended September 30, 2025 (Based on Japanese GAAP)
D.Western Therapeutics Institute, Jan-Sep (Cumulative 3Q) Net Income Loss Narrows, Jul-Sep Net Income Loss Narrows
Notice Concerning Results of Joint Research with DKS Co. Ltd.
DW-5LBT "Bondlido" Approved in the US for the Treatment of Post-Herpetic Neuralgia
Change of Proprietary Name for DW-5LBT
D.Western Therapeutics Institute, First Half Net Income Loss Narrows, Apr-Jun Net Income Loss Narrows
Q2 FY12/25 Financial Results Briefing Materials
Consolidated Financial Results for the Six Months Ended June 30, 2025 (Based on Japanese GAAP)
Announcement regarding the decision to develop a new pipeline“H-1129”
Announcement of Launch in Thailand for Glaucoma and Ocular Hypertension Treatment“GLA-ALPHA Combination Ophthalmic Solution (Japanese product name)”
Announcement regarding the commencement of joint research with Chordia Therapeutics Inc.
Notification of Approval in Singapore for Glaucoma and Ocular Hypertension Treatment “GLA-ALPHA Combination Ophthalmic Solution”
Announcement of completion of subject dosing in global Phase III clinical trial of "K-321," a treatment for Fuchs endothelial corneal dystrophy
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)